Shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) have earned a consensus recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $31.75.

A number of analysts have commented on the stock. Morgan Stanley began coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They issued an “overweight” rating for the company. Needham & Company LLC began coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 price objective on the stock. Piper Jaffray Companies began coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 price objective on the stock. Zacks Investment Research lowered shares of Biohaven Pharmaceutical Holding Co from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, William Blair began coverage on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued an “outperform” rating and a $46.00 price objective on the stock.

WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Receives Average Rating of “Buy” from Analysts” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-ltd-bhvn-receives-average-rating-of-buy-from-analysts/1496398.html.

Biohaven Pharmaceutical Holding Co (BHVN) traded up 4.27% on Wednesday, hitting $25.64. 139,980 shares of the stock traded hands. Biohaven Pharmaceutical Holding Co has a 52 week low of $17.00 and a 52 week high of $28.34. The stock’s market cap is $916.58 million. The firm’s 50 day moving average is $24.97 and its 200 day moving average is $23.86.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.